Brief: Matinas Biopharma Holdings Reports Positive Interim Data From The Phase 2 Enact Trial Of Mat2203
21/10/2022 13:46
Oct 21 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA HOLDINGS - REPORTS POSITIVE INTERIM DATA
FROM
THE PHASE 2 ENACT TRIAL OF MAT2203 FOR TREATMENT OF CRYPTOCOCCAL
MENINGITIS
* MATINAS BIOPHARMA HOLDINGS INC - COHORT 4 (AN ALL-ORAL
TREATMENT
REGIMEN WITH MAT2203) MET ITS PRESPECIFIED PRIMARY ENDPOINT
* MATINAS BIOPHARMA - PLANS TO INITIATE A PHASE 3
REGISTRATION
TRIAL OF MAT2203 AS STEP-DOWN THERAPY IN CRYPTOCOCCAL MENINGITIS
IN Q1 OF 2023
* MATINAS BIOPHARMA HOLDINGS - OVERALL SURVIVAL IN COHORT 4,
A KEY
SECONDARY ENDPOINT OF THE STUDY, IS 95 % AT TWO WEEKS AND
CURRENTLY 90% OVERALL
Source: (shorturl.at/clBWZ)
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing